ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2010
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The prognostic significance of p53 expression in gastric cancer: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis.Digestive diseases and sciences · 2014Pooled it
- Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: a meta-analysis.BioMed research international · 2014Pooled it
- Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.BMC cancer · 2013Pooled it
- Prostaglandin ETheranostics · 2019Trial
- Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.Medicine · 2017Trial
- Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells.Journal, genetic engineering & biotechnology · 2025Article
- CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression.Cancer biology & therapy · 2023Article
- The Role of Lipid Metabolism in Gastric Cancer.Frontiers in oncology · 2022Review
- HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression.Disease markers · 2022Article
- Genetic Variations in Prostaglandin EInternational journal of molecular sciences · 2021Article
- Prostaglandin EInternational journal of molecular sciences · 2020Article
- The molecular mechanisms of celecoxib in tumor development.Medicine · 2020Article
- Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.Journal of pathology and translational medicine · 2020Article
- Article
- Significance of Cyclooxygenase-2 in Oncogenesis.Journal of veterinary research · 2019Article
- Insights into gastric neuroendocrine tumors burden.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
- Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray.Molecular & cellular proteomics : MCP · 2016Article
- Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclooxygenase-2 (COX-2) is an important factor in gastric carcinogenesis, and COX-2 expression in gastric cancer patients correlates with prognosis. We have now studied the impact of COX-2 in comparison to six other tissue tumor markers, DNA index, and S-phase fraction (SPF) in a large series of gastric cancer specimens. From 342 consecutive patients, 337 archival tissue specimens were available for immunohistochemistry of COX-2, HuR, cyclin A, MMP-2, p53, p21, and Ki-67 and 313 for analysis of DNA index and S-phase fraction by flow cytometry. Associations between factors were assessed by chi-square test and survival analysis by the Kaplan-Meier method and Cox model. A significant association emerged between of COX-2 and p53 (p < 0.0001), Ki-67 (p = 0.013), DNA ploidy (p < 0.0001), and SPF (p < 0.0001). In an extended multivariate analysis, COX-2 and p53 expression were independent prognostic factors for poor survival, in addition to high stage and non-curative surgery. In gastric cancer, COX-2 expression associated with markers for apoptosis and proliferation, and furthermore, it was confirmed that COX-2 and p53 are strong prognostic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.